Key result
Peak endocardial acceleration measured by an endocardial accelerometer significantly decreased by 7% (0.91 to 0.85 g, P<0.05) during acute myocardial ischemia in patients undergoing PTCA.
Why the study?
Can an endocardial accelerometer detect acute myocardial ischemia in patients undergoing PTCA?
Observational (n=13)
Can an endocardial accelerometer detect acute myocardial ischemia in patients undergoing PTCA?
Effect estimate: 7% decrease
Absolute Event Rate: 0.85% vs 0.91%
p-value: p=<0.05
Endocardial acceleration parameters significantly decrease during acute myocardial ischemia induced by PTCA, suggesting potential for real-time ischemia monitoring using an endocardial accelerometer.
Suggests endocardial accelerometers could monitor ischemia during PTCA; leaves open prospective validation before clinical adoption.
The first heart sound is generated by vibrations from the myocardium during isovolumic contraction. Peak endocardial acceleration (PEA) has been used previously to measure these vibrations in humans and correlates with myocardial contractility during inotropic interventions. It is unknown if changes in PEA can be used to characterize a reduction in contractility during ischemic episodes. This study was designed to evaluate the use of an endocardial accelerometer for the detection of acute myocardial ischemia. Thirteen patients undergoing routine percutaneous transluminal coronary angioplasty (PTCA) consented to having a single-axis, lead-based accelerometer positioned in the right ventricular apex. PEA was defined as the maximum peak-to-peak amplitude during a window 50 ms before to 200 ms following the peak R wave. Time of endocardial acceleration (TEA) was defined as the time from the peak R wave to the maximum accelerometer signal within this window. To obtain a more robust estimate of the strength of vibrations, a 100-beat template of the accelerometer signal was constructed at baseline and applied as a matched filter during ischemia. The peak magnitude of the filtered endocardial accelerometer signal (Max Filtered EA) was used as an index of signal intensity. Median baseline PEA, TEA, and Max Filtered EA were 0.91 +/- 0.35 g, 75.2 +/- 16.2 ms, and 0.40 +/- 0.20 g, respectively. PEA and Max Filtered EA significantly decreased by 7% during ischemia (0.91 to 0.85 g and 0.40 to 0.37 g, both P < 0.05, respectively). TEA did not significantly change from baseline (77.0 ms, P = ns). The results of this study suggest that acute ischemia can be detected with an endocardial accelerometer in humans.
No takes yet. Share an insight, caveat, or question.
Theres et al. (2004) conducted an observational in Acute myocardial ischemia (n=13). Endocardial accelerometer vs. Baseline (pre-ischemia) was evaluated on Peak endocardial acceleration (PEA) (7% decrease, p=<0.05). Peak endocardial acceleration measured by an endocardial accelerometer significantly decreased by 7% (0.91 to 0.85 g, P<0.05) during acute myocardial ischemia in patients undergoing PTCA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: